PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV
- PMID: 38839923
- PMCID: PMC11153591
- DOI: 10.1038/s41598-024-63595-7
PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV
Abstract
Programmed death-ligand 1 (PD-L1) is overexpressed in squamous cervical cancer (SCC) and can be used for targeted immunotherapy. The highest mortality rates of SCC are reported in sub-Saharan Africa, where Human immunodeficiency virus (HIV) prevalence is high. In Mozambique most SCC patients present at advanced stages. Thus, there is a need to introduce new treatment options. However, immunocompromised patients were frequently excluded in previous clinical trials. Our aim was to determine if PD-L1 expression in SCC is as prevalent among women living with HIV (WLWH) as among other patients. 575 SCC from Maputo Central Hospital were included. HIV status was available in 266 (46%) cases PD-L1 expression was scored through tumour proportion score (TPS) and combined positive score (CPS). PD-L1 was positive in 20.1% of the cases (n = 110), TPS (score ≥ 25%) and in 26.3% (n = 144), CPS (score ≥ 1). Stratifying according to the HIV status, WLWH were TPS positive in 16.7%, compared to 20.9%, p = 0.43, and concerning CPS 21.1% versus 28.7%, p = 0.19, respectively. PD-L1 status was not influenced by stage, Ki-67 or p16, CD8 expression influenced only CPS status. Our data indicates that the documented effect of PD-L1 therapy on SCC should be confirmed in randomized clinical trials in an HIV endemic milieu.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures


Similar articles
-
Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.Virchows Arch. 2024 Mar;484(3):507-516. doi: 10.1007/s00428-023-03580-z. Epub 2023 Jun 21. Virchows Arch. 2024. PMID: 37341812 Free PMC article.
-
Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer.Int J Gynecol Pathol. 2025 Mar 1;44(2):104-111. doi: 10.1097/PGP.0000000000001051. Epub 2024 Jun 12. Int J Gynecol Pathol. 2025. PMID: 38914017
-
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.J Obstet Gynaecol Res. 2017 Oct;43(10):1602-1612. doi: 10.1111/jog.13411. Epub 2017 Aug 17. J Obstet Gynaecol Res. 2017. PMID: 28833798
-
PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.Histopathology. 2019 Jan;74(2):256-268. doi: 10.1111/his.13723. Epub 2018 Oct 29. Histopathology. 2019. PMID: 30067880
-
Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.Cancer Rep (Hoboken). 2024 Apr;7(4):e2057. doi: 10.1002/cnr2.2057. Cancer Rep (Hoboken). 2024. PMID: 38662366 Free PMC article.